Cellular uptake and trafficking of antisense oligonucleotides

Nature Biotechnology

Volumn 35, Issue 3, 2017, Pages 230-237

  Crooke, Stanley T ^a   Wang, Shiyu ^a   Vickers, Timothy A ^a   Shen, Wen ^a   Liang, Xue Hai ^a  

^a ISIS PHARMACEUTICALS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOLOGY; GENE EXPRESSION; OLIGONUCLEOTIDES; PROTEINS; RNA;

ANTISENSE OLIGONUCLEOTIDES; CELLULAR UPTAKE; FAMILIAL HYPERCHOLESTEROLEMIA; INTRACELLULAR DISTRIBUTION; PHOSPHOROTHIOATES; PROTEIN INTERACTION; SPECIFIC CLEAVAGES; SPINAL MUSCULAR ATROPHY;

NUCLEIC ACIDS;

ANTISENSE OLIGODEOXYNUCLEOTIDE; CELL PROTEIN; PHOSPHOROTHIOIC ACID; RIBONUCLEASE H; ANTISENSE OLIGONUCLEOTIDE;

CELL MIGRATION; CELL TRANSPORT; CELLULAR DISTRIBUTION; CYTOPLASM; GENETIC TRANSFECTION; HUMAN; MAMMAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; REVIEW; UPTAKE ASSAY; ANIMAL; CELL FRACTIONATION; CELL MEMBRANE; GENE THERAPY; GENETICS; METABOLISM; PROCEDURES; STRUCTURE ACTIVITY RELATION;

ANIMALS; CELL MEMBRANE; GENETIC THERAPY; HUMANS; OLIGONUCLEOTIDES, ANTISENSE; STRUCTURE-ACTIVITY RELATIONSHIP; SUBCELLULAR FRACTIONS;

EID: 85014750221     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.3779     Document Type: Review

References (64)

1. Crooke, S. T., Vickers, T., Lima, W., Wu, H.-J. in Antisense Drug Technology-Principles, Strategies, Application 2nd edn. (ed. Crooke, S. T. ) 3-46 (CRC Press, Boca Raton, FL, 2008).
2. Evers, M. M., Toonen, L. J. A., van Roon-Mom, W. M. C. Antisense oligonucleotides in therapy for neurodegenerative disorders. Adv. Drug Deliv. Rev. 87, 90-103 (2015).
3. Brown, D. A., et al. Effect of phosphorothioate modification of oligodeoxynucleotides on specific protein binding. J. Biol. Chem. 269, 26801-26805 (1994).
4. Liang, X. H., Sun, H., Shen, W., Crooke, S. T. Identification and characterization of intracellular proteins that bind oligonucleotides with phosphorothioate linkages. Nucleic Acids Res. 43, 2927-2945 (2015).
5. Swayze, E. E., Bhat, B. in Antisense Drug Technology-Principles, Strategies, Application 2nd edn. (ed. Crooke, S. T. ) 143-182 (CRC Press, Boca Raton, FL, 2008).
6. Geary, R. S., Yu, R. Z., Siwkoswki, A., Leivin, A. A. in Antisense Drug Technology-Principles, Strategies, Application 2nd edn. (ed. Crooke, S. T. ) 305-326 (CRC Press, Boca Raton, FL. 2008).
7. Dias, N., Stein, C. A. Antisense oligonucleotides: basic concepts and mechanisms. Mol. Cancer Ther. 1, 347-355 (2002).
8. Kurreck, J. Antisense technologies. Improvement through novel chemical modifications. Eur. J. Biochem. 270, 1628-1644 (2003).
9. Lee, R. G., Crosby, J., Baker, B. F., Graham, M. J., Crooke, R. M. Antisense technology: an emerging platform for cardiovascular disease therapeutics. J. Cardiovasc. Transl. Res. 6, 969-980 (2013).
10. Bennett, C. F., Swayze, E. E. RNA targeting therapeutics: molecular mechanisms of antisense oligonucleotides as a therapeutic platform. Annu. Rev. Pharmacol. Toxicol. 50, 259-293 (2010).
11. Geary, R. S., Norris, D., Yu, R., Bennett, C. F. Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides. Adv. Drug Deliv. Rev. 87, 46-51 (2015).
12. Trülzsch, B., Wood, M. Applications of nucleic acid technology in the CNS. J. Neurochem. 88, 257-265 (2004).
13. Juliano, R. L. The delivery of therapeutic oligonucleotides. Nucleic Acids Res. 44, 6518-6548 (2016).
14. Vlassov, V. V., Vlassova, I. E., Pautova, L. V. Oligonucleotides and polynucleotides as biologically active compounds. Prog. Nucleic Acid Res. Mol. Biol. 57, 95-143 (1997).
15. Iversen, P. L., Zhu, S., Meyer, A., Zon, G. Cellular uptake and subcellular distribution of phosphorothioate oligonucleotides into cultured cells. Antisense Res. Dev. 2, 211-222 (1992).
16. Ugarte-Uribe, B., et al. Synthesis, cell-surface binding, cellular uptake of fluorescently labeled glucose-DNA conjugates with different carbohydrate presentation. Bioconjug. Chem. 21, 1280-1287 (2010).
17. Cheng, C. J., Saltzman, W. M. Enhanced siRNA delivery into cells by exploiting the synergy between targeting ligands and cell-penetrating peptides. Biomaterials 32, 6194-6203 (2011).
18. Yu, C., Brussaard, A. B., Yang, X., Listerud, M., Role, L. W. Uptake of antisense oligonucleotides and functional block of acetylcholine receptor subunit gene expression in primary embryonic neurons. Dev. Genet. 14, 296-304 (1993).
19. Koller, E., et al. Mechanisms of single-stranded phosphorothioate modified antisense oligonucleotide accumulation in hepatocytes. Nucleic Acids Res. 39, 4795-4807 (2011).
20. Juliano, R. L., Ming, X., Carver, K., Laing, B. Cellular uptake and intracellular trafficking of oligonucleotides: implications for oligonucleotide pharmacology. Nucleic Acid Ther. 24, 101-113 (2014).
21. Juliano, R. L., Carver, K., Cao, C., Ming, X. Receptors, endocytosis, trafficking: the biological basis of targeted delivery of antisense and siRNA oligonucleotides. J. Drug Target. 21, 27-43 (2013).
22. Goldsack, N. C., et al. Integrin mediated uptake of antisense oligonucleotides to the PAR-1 thrombin receptor inhibits thrombin induced fibroblast proliferation. FASEB J. 12, A434 (1998).
23. Alam, M. R., et al. Intracellular delivery of an anionic antisense oligonucleotide via receptor-mediated endocytosis. Nucleic Acids Res. 36, 2764-2776 (2008).
24. Ming, X., et al. Intracellular delivery of an antisense oligonucleotide via endocytosis of a G-protein-coupled receptor. Nucleic Acids Res. 38, 6567-6576 (2010).
25. Miller, C. M., et al. Stabilin-1 and Stabilin-2 are specific receptors for the cellular internalization of phosphorothioate-modified antisense oligonucleotides (ASOs) in the liver. Nucleic Acids Res. 44, 2782-2794 (2016).
26. Ezzat, K., et al. Self-Assembly into Nanoparticles Is Essential for Receptor Mediated Uptake of Therapeutic Antisense Oligonucleotides. Nano Lett. 15, 4364-4373 (2015).
27. Kortylewski, M., et al. In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. Nat. Biotechnol. 27, 925-932 (2009).
28. Kandimalla, E. R., et al. Design, synthesis and biological evaluation of novel antagonist compounds of Toll-like receptors 7, 8 and 9. Nucleic Acids Res. 41, 3947-3961 (2013).
29. Weidner, D. A., Valdez, B. C., Henning, D., Greenberg, S., Busch, H. Phosphorothioate oligonucleotides bind in a non-sequence-specific manner to the nucleolar protein C23/nucleolin. FEBS Lett. 366, 146-150 (1995).
30. Kotula, J. W., et al. Aptamer-mediated delivery of splice-switching oligonucleotides to the nuclei of cancer cells. Nucleic Acid Ther. 22, 187-195 (2012).
31. Sahay, G., et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653-658 (2013).
32. Gilleron, J., et al. Image-based analysis of lipid nanoparticle-mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638-646 (2013).
33. Beltinger, C., et al. Binding, uptake, intracellular trafficking of phosphorothioate-modified oligodeoxynucleotides. J. Clin. Invest. 95, 1814-1823 (1995).
34. Bennett, C. F. in Antisense Drug Technology-Principles, Strategies, Application2nd edn. (ed. Crooke, S. T. ) 273-304 (CRC Press, Boca Raton, FL, 2006).
35. Mou, T. C., Gray, D. M. The high binding affinity of phosphorothioate-modified oligomers for Ff gene 5 protein is moderated by the addition of C-5 propyne or 2-O-methyl modifications. Nucleic Acids Res. 30, 749-758 (2002).
36. Liang, X. H., et al. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2-modifications and enhances antisense activity. Nucleic Acids Res. 44, 3892-3907 (2016).
37. Juliano, R. L., Ming, X., Nakagawa, O. Cellular uptake and intracellular trafficking of antisense and siRNA oligonucleotides. Bioconjug. Chem. 23, 147-157 (2012).
38. Juliano, R. L., Carver, K. Cellular uptake and intracellular trafficking of oligonucleotides. Adv. Drug Deliv. Rev. 87, 35-45 (2015).
39. Reyes-Reyes, E. M., Teng, Y., Bates, P. J. A new paradigm for aptamer therapeutic AS1411 action: uptake by macropinocytosis and its stimulation by a nucleolin-dependent mechanism. Cancer Res. 70, 8617-8629 (2010).
40. Alam, M. R., et al. The biological effect of an antisense oligonucleotide depends on its route of endocytosis and trafficking. Oligonucleotides 20, 103-109 (2010).
41. Stein, C. A., et al. Efficient gene silencing by delivery of locked nucleic acid antisense oligonucleotides, unassisted by transfection reagents. Nucleic Acids Res. 38 e3 (2010).
42. Ming, X., Sato, K., Juliano, R. L. Unconventional internalization mechanisms underlying functional delivery of antisense oligonucleotides via cationic lipoplexes and polyplexes. J. Control. Release 153, 83-92 (2011).
43. Biessen, E. A., Vietsch, H., Kuiper, J., Bijsterbosch, M. K., Berkel, T. J. Liver uptake of phosphodiester oligodeoxynucleotides is mediated by scavenger receptors. Mol. Pharmacol. 53, 262-269 (1998).
44. El-Sayed, A., Harashima, H. Endocytosis of gene delivery vectors: from clathrin-dependent to lipid raft-mediated endocytosis. Mol. Ther. 21, 1118-1130 (2013).
45. Prakash, T. P., et al. Targeted delivery of antisense oligonucleotides to hepatocytes using triantennary N-acetyl galactosamine improves potency 10-fold in mice. Nucleic Acids Res. 42, 8796-8807 (2014).
46. Wada, S., et al. Evaluation of the effects of chemically different linkers on hepatic accumulations, cell tropism and gene silencing ability of cholesterol-conjugated antisense oligonucleotides. J. Control. Release 226, 57-65 (2016).
47. Vickers, T. A., Crooke, S. T. Development of a quantitative BRET affinity assay for nucleic acid-protein interactions. PLoS One 11, e0161930 (2016).
48. Wang, S., Sun, H., Tanowitz, M., Liang, X. H., Crooke, S. T. Annexin A2 facilitates endocytic trafficking of antisense oligonucleotides. Nucleic Acids Res. 44, 7314-7330 (2016).
49. Shen, W., Liang, X. H., Crooke, S. T. Phosphorothioate oligonucleotides can displace NEAT1 RNA and form nuclear paraspeckle-like structures. Nucleic Acids Res. 42, 8648-8662 (2014).
50. Machleidt, T., et al. NanoBRET-a novel BRET platform for the analysis of protein-protein interactions. ACS Chem. Biol. 10, 1797-1804 (2015).
51. Chin, D. J., Green, G. A., Zon, G., Szoka, F. C. Jr., Straubinger, R. M. Rapid nuclear accumulation of injected oligodeoxyribonucleotides. New Biol. 2, 1091-1100 (1990).
52. Bennett, C. F., Chiang, M. Y., Chan, H., Shoemaker, J. E., Mirabelli, C. K. Cationic lipids enhance cellular uptake and activity of phosphorothioate antisense oligonucleotides. Mol. Pharmacol. 41, 1023-1033 (1992).
53. Leonetti, J. P., Mechti, N., Degols, G., Gagnor, C., Lebleu, B. Intracellular distribution of microinjected antisense oligonucleotides. Proc. Natl. Acad. Sci. USA88, 2702-2706 (1991).
54. Lorenz, P., Baker, B. F., Bennett, C. F., Spector, D. L. Phosphorothioate antisense oligonucleotides induce the formation of nuclear bodies. Mol. Biol. Cell 9, 1007-1023 (1998).
55. Lorenz, P., Misteli, T., Baker, B. F., Bennett, C. F., Spector, D. L. Nucleocytoplasmic shuttling: a novel in vivo property of antisense phosphorothioate oligodeoxynucleotides. Nucleic Acids Res. 28, 582-592 (2000).
56. Liang, X. H., Shen, W., Sun, H., Prakash, T. P., Crooke, S. T. TCP1 complex proteins interact with phosphorothioate oligonucleotides and can co-localize in oligonucleotide-induced nuclear bodies in mammalian cells. Nucleic Acids Res. 42, 7819-7832 (2014).
57. Marcusson, E. G., Bhat, B., Manoharan, M., Bennett, C. F., Dean, N. M. Phosphorothioate oligodeoxyribonucleotides dissociate from cationic lipids before entering the nucleus. Nucleic Acids Res. 26, 2016-2023 (1998).
58. Zelphati, O., Szoka, F. C. Jr. Mechanism of oligonucleotide release from cationic liposomes. Proc. Natl. Acad. Sci. USA 93, 11493-11498 (1996).
59. Tarkanyi, I., et al. Inhibition of human telomerase by oligonucleotide chimeras, composed of an antisense moiety and a chemically modified homo-oligonucleotide. FEBS Lett. 579, 1411-1416 (2005).
60. Castanotto, D., et al. A cytoplasmic pathway for gapmer antisense oligonucleotide-mediated gene silencing in mammalian cells. Nucleic Acids Res. 43, 9350-9361 (2015).
61. Kubo, T., et al. Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation. Org. Biomol. Chem. 3, 3257-3259 (2005).
62. Juliano, R., Bauman, J., Kang, H., Ming, X. Biological barriers to therapy with antisense and siRNA oligonucleotides. Mol. Pharm. 6, 686-695 (2009).
63. Yang, B., et al. High-throughput screening identifies small molecules that enhance the pharmacological effects of oligonucleotides. Nucleic Acids Res. 43, 1987-1996 (2015).
64. Vickers, T. A., Crooke, S. T. Antisense oligonucleotides capable of promoting specific target mRNA reduction via competing RNase H1-dependent and independent mechanisms. PLoS One 9, e108625 (2014).